Search

Your search keyword '"Sellier, Pierre-Olivier"' showing total 2 results
Start Over Author "Sellier, Pierre-Olivier" Journal aids london england
2 results on '"Sellier, Pierre-Olivier"'

1. Prescriptions of generic antiretroviral drugs in three healthcare centers in the Paris area, France.

Author

Leroy P, Diamantis S, Sellier PO, Hamet G, Brun A, Rozenbaum W, and Molina JM

Subjects
Humans, Retrospective Studies, Female, Male, Middle Aged, Paris, Adult, Anti-Retroviral Agents therapeutic use, Drug Prescriptions statistics & numerical data, Aged, Drug Utilization statistics & numerical data, Anti-HIV Agents therapeutic use, Drugs, Generic therapeutic use, HIV Infections drug therapy
Abstract

In a retrospective study conducted in three hospitals in Paris, generic antiretroviral accounted for 30.2% of all prescriptions. Tenofovir disoproxil/emtricitabine (TDF/FTC) was the most prescribed generic ART (82.3% of generic prescriptions). Generic ART (gART) was more likely to be prescribed to women, to patients less than 50 years, and with recent HIV diagnosis less than 3 years. Physicians prescribed more gART if they were men, older than 55 years or worked at a university teaching hospital., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

2. Low cabotegravir trough concentrations without oral lead-in in patients with HIV-1 switching to long-acting cabotegravir and rilpivirine.

Author

Rubenstein E, Diemer M, Goldwirt L, Lascoux-Combe C, Chaix ML, Rami A, Ponscarme D, Lafaurie M, Denis B, De Castro N, Gras J, Liegeon G, Sellier PO, Deville L, Chevret S, Delaugerre C, and Molina JM

Subjects
Humans, Male, Female, Middle Aged, Adult, Drug Substitution, Administration, Oral, Plasma chemistry, Diketopiperazines, Pyridones administration & dosage, Rilpivirine administration & dosage, Rilpivirine therapeutic use, Rilpivirine pharmacokinetics, HIV Infections drug therapy, Anti-HIV Agents administration & dosage, Anti-HIV Agents pharmacokinetics, Anti-HIV Agents therapeutic use, HIV-1 isolation & purification
Abstract

In a cohort of 72 consecutive virologically-suppressed patients with HIV-1 switching to long-acting cabotegravir and rilpivirine, we observed low cabotegravir trough concentrations 1 and 3 months after the first injection, with a significant association with no oral lead-in at 1 month [odds ratio (OR) = 6.3 [95% confidence interval (CI) 1.7-29.5], P = 0.01] and three months (OR = 5.6 [95% CI 1.3-29.7], P = 0.03), and with high BMI at 1 month (OR = 1.3 [95% CI 1.1-1.6], P = 0.007)., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results